Luminex Corporation to Webcast Annual Investor Presentation
AUSTIN, Texas, March 1 -- Luminex Corporation (NASDAQ:LMNX) today announced that senior management will host an institutional investor and financial analyst luncheon on Thursday, March 25, 2010, at 11:00 a.m. EDT at the NASDAQ MarketSite, in New York City. Luminex management will review the Company's financial progress, operating highlights and strategic initiatives, and will provide an update on product development activities followed by a question and answer session.
The investor presentation led by Patrick J. Balthrop, president and chief executive officer, will begin at 11:30 a.m. Eastern time. In addition to presentations by senior management, the event will feature presentations by industry thought leaders, Dr. Andrea Ferreira-Gonzalez, Professor of Pathology and Director of the Molecular Diagnostics Lab at Virginia Commonwealth University, and Dr. Thomas Joos, Head of Biochemistry, NMI Natural and Medical Sciences Institute at the University of Tuebingen. The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com/.
Investor Event Registration:
In order to register for the event, simply log on to the website at the address above, go to the Company section and access the Investor Relations link or go directly to the registration page, click on, or paste the following link in your web browser:
Please go to the website prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.
NASDAQ Opening Bell Ceremony:
Patrick J. Balthrop, president and chief executive officer, will ring The NASDAQ Stock Market Opening Bell on March 25, 2010 at 9:30 EDT at the NASDAQ MarketSite in Times Square, New York, NY. The bell ringing commemorates Luminex' 10th anniversary of trading on NASDAQ.
Luminex commenced trading on The NASDAQ National Market in New York on March 30, 2000. Since then, Luminex has experienced tremendous growth, achieving an installed base of over 6700 multiplexing instruments, expanding into new market segments such as molecular diagnostics and entering new geographies such as China and Japan.
The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.
ABOUT LUMINEX CORPORATION
Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP® technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP® can be obtained on the Internet at http://www.luminexcorp.com/.
Contacts: Harriss T. Currie Mimi L. Torrington
Vice President, Finance and Chief Director of Investor
Financial Officer Relations
CONTACT: Harriss T. Currie, Vice President, Finance and Chief Financial
Officer, email@example.com, or Mimi L. Torrington, Director of Investor
Relations, firstname.lastname@example.org, both of Luminex Corporation,